TENX

Tenax TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-21

Current thesis

TENX now has a defined registrational setup: LEVEL hit its randomization target, topline data are expected in Q3 2026, and LEVEL-2 has begun, creating a credible pathway to a material re-rate if efficacy replicates prior promise in PH-HFpEF [#8-K-2026-03-10].

Posture

Mixed

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta -0.2.

What can break

Capital raise or partnership terms become the dominant narrative before pivotal data arrive.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $12.00 · Bull $18.00 · Bear $7.00

Data freshness

Prices

As of 2026-07-21

Fundamentals

As of 2026-07-21 • Vendor: Data Vendor v1

Scores

As of 2026-07-21 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-17 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-21

Supporting evidence

What

Grade C · Mixed

Confidence Medium · Net Neutral

Target $34.71

Why

Momentum97 · Δ7d -0.2

Value41 · Δ7d +0.1

Sentiment24 · Δ7d -0.0

So what

Balanced signals (Net Neutral). Wait for confirmation before sizing up.

Lead driver: Momentum · See technicals

Momentum

26% active weight

Current posture

7d trendFlat

Δ7d

-0.2

Δ21d

+60.0

Value

39% active weight

Current posture

7d trendFlat

Δ7d

+0.1

Δ21d

-0.0

Sentiment

34% active weight

Current posture

7d trendFlat

Δ7d

-0.0

Δ21d

-15.4

Why this grade

Composite grade C. Momentum 97.0 / Value 41.1 / Sentiment 23.7

Fundamentals (TTM)

As of 2026-07-21

Market Cap

$416.98M

Beta

1.41

Shares Out

26.53M

P/E (TTM) · Derived

-11.7

P/S (TTM)

P/FCF (TTM) · Derived

-17.04

Rev YoY

-100.0%

EPS YoY

+22.1%

Gross Margin

Op Margin

Net Debt

-$97.57M

Current Ratio

14.52

As of 2026-07-21 • Updated nightlySource: Internal modelMethodology